Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC lifted its stake in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 27.7% during the fourth quarter, Holdings Channel reports. The fund owned 11,714 shares of the company’s stock after purchasing an additional 2,540 shares during the quarter. SG Americas Securities LLC’s holdings in Entrada Therapeutics were worth $177,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Ameritas Investment Partners Inc. acquired a new stake in shares of Entrada Therapeutics during the second quarter valued at $27,000. Royal Bank of Canada acquired a new stake in Entrada Therapeutics in the 2nd quarter worth about $34,000. Lazard Asset Management LLC acquired a new stake in Entrada Therapeutics in the 2nd quarter worth about $36,000. Legal & General Group Plc acquired a new stake in Entrada Therapeutics in the 4th quarter worth about $40,000. Finally, Tower Research Capital LLC TRC acquired a new stake in Entrada Therapeutics in the 3rd quarter worth about $40,000. Institutional investors and hedge funds own 86.39% of the company’s stock.

Entrada Therapeutics Price Performance

Entrada Therapeutics stock opened at $12.95 on Monday. The stock’s 50-day moving average is $13.48 and its 200-day moving average is $14.44. The company has a market cap of $435.12 million, a price-to-earnings ratio of -49.81 and a beta of -0.50. Entrada Therapeutics, Inc. has a 12 month low of $10.62 and a 12 month high of $18.44.

Entrada Therapeutics (NASDAQ:TRDA) last released its quarterly earnings data on Wednesday, March 13th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.22). The firm had revenue of $41.85 million during the quarter, compared to analysts’ expectations of $27.82 million. Entrada Therapeutics had a negative return on equity of 2.89% and a negative net margin of 5.18%. Research analysts anticipate that Entrada Therapeutics, Inc. will post -1.54 EPS for the current year.

Insider Transactions at Entrada Therapeutics

In other news, Director Peter S. Kim acquired 2,600 shares of the business’s stock in a transaction dated Monday, April 8th. The shares were bought at an average cost of $13.57 per share, for a total transaction of $35,282.00. Following the acquisition, the director now directly owns 62,936 shares in the company, valued at approximately $854,041.52. The purchase was disclosed in a filing with the SEC, which is available through this link. In related news, Director Peter S. Kim bought 3,180 shares of the company’s stock in a transaction that occurred on Monday, March 25th. The shares were acquired at an average cost of $13.36 per share, for a total transaction of $42,484.80. Following the acquisition, the director now owns 56,074 shares in the company, valued at approximately $749,148.64. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Peter S. Kim bought 2,600 shares of the company’s stock in a transaction that occurred on Monday, April 8th. The shares were bought at an average price of $13.57 per share, for a total transaction of $35,282.00. Following the completion of the acquisition, the director now owns 62,936 shares in the company, valued at approximately $854,041.52. The disclosure for this purchase can be found here. Insiders have bought a total of 8,896 shares of company stock worth $119,272 in the last three months. 7.58% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of analysts have issued reports on TRDA shares. Oppenheimer started coverage on Entrada Therapeutics in a research note on Friday, January 5th. They issued an “outperform” rating and a $22.00 price target on the stock. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Entrada Therapeutics in a research note on Monday, March 18th.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.